Immunomodulators such as methotrexate and azathioprine act by reducing T-cell proliferation and cytokine release, while TNF-α inhibitors (e.g., infliximab) specifically block TNF-α signaling, a key driver of granuloma persistence [6]. This evidence concerns the gene TNF and Granuloma.